We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » More Specific Guidance Requests Expected in Biosimilars Comments
More Specific Guidance Requests Expected in Biosimilars Comments
March 27, 2012
BALTIMORE — Drugmakers are expected to push for details on how the FDA will review biosimilars applications that reference biologics approved outside the U.S.